ClinicalTrials.gg
Not yet recruitingNCT07862400Updated Oct 9, 2026

A Pilot Study on the Efficacy of Oral Low Dose Naltrexone for Vulvodynia

A Phase 2 interventional study of Low Dose Naltrexone in Vulvodynia, sponsored by University of Florida. Not yet recruiting at 2 sites in United States. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Florida · Phase 2, Interventional, and Treatment

How we know

Updated Oct 9, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Vulvodynia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Vulvodynia · United States.

Planned enrollment
25th of 36
20 · median 45
Started
2027
the only one that year
Phase 2
10 of 47
3 open now
Registered
47th of 47
by date

Among the 47 studies in Vulvodynia with a site in United States, this one is the 25th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2027, is one of 10 in phase 2, and was the 47th registered.

Vulvodynia

117 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.

Browse Vulvodynia studies →

Open to participants now

8 of the 47 studies in Vulvodynia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Vulvodynia studies recruiting now, 8 (62%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Vulvodynia with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational pilot study is to assess the safety, efficacy, and tolerability of oral low dose naltrexone (LDN) in the treatment of vulvodynia. The aims it will address are:

Aim 1:To assess the efficacy of LDN by reviewing patient-reported Global Treatment Improvement scale scores after the 4-week treatment period.

Aim 2: To identify the impact on overall and vulvar pain by calculating the difference between average pre- and post-treatment PGIC, NRS, CSI and VPAQ scores.

Aim 3: To identify adverse effects that patients may experience during treatment to better understand the safety profile of this medication.

Participants will [describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items]

  • Attend a baseline clinic visit and complete PGIC, NRS, VPAQ, and CSI questionnaires
  • Take 4.5 mg LDN once daily for 4 weeks
  • Discontinue LDN and contact the health care team immediately in the event of adverse effects
  • Attend a follow up appointment 4 weeks after medication initiation
Read the detailed description

Vulvodynia is a chronic vulvar pain condition characterized by persistent vulvar pain or discomfort without an identifiable cause. The condition can substantially affect quality of life, including sexual function, emotional well-being, and social functioning. The etiology of vulvodynia is multifactorial and may involve peripheral nerve dysfunction, hormonal factors, pelvic floor dysfunction, and altered central pain processing.

Available treatments for vulvodynia include topical medications, pelvic floor physical therapy, systemic medications, behavioral interventions, injections, and other procedural therapies. Treatment response is variable, and some participants continue to experience clinically significant symptoms despite conventional management. Additional treatment options with acceptable tolerability are therefore needed.

Low-dose naltrexone (LDN) is a low-dose formulation of naltrexone that has been investigated for the management of several chronic pain conditions. Proposed mechanisms include modulation of neuroinflammatory pathways and reduction of inflammatory signaling within the central nervous system. The potential effects of LDN on vulvodynia-related pain remain insufficiently characterized, supporting further clinical investigation.

This pilot study will evaluate the safety, tolerability, and potential effectiveness of oral LDN for the treatment of vulvodynia. The study will enroll approximately 20 adult female participants with vulvodynia. Participants will receive oral LDN at a dose of 4.5 mg once daily for four weeks.

The study will consist of screening, a four-week treatment period, and post-treatment follow-up. Screening procedures will include confirmation of eligibility, collection of demographic and clinical information, medication review, pregnancy testing when applicable, assessment of baseline pain and symptoms, and laboratory testing. Baseline assessment will include a comprehensive clinical evaluation and validated measures of pain and vulvodynia-related symptoms. A pelvic floor and vulvar assessment will be performed as clinically appropriate and according to the study protocol.

Before initiation of LDN, participants will record daily vulvar pain scores for seven consecutive days using the Numerical Rating Scale (NRS). The average baseline NRS score will be calculated from the seven-day recording period. Validated questionnaires will also be administered at baseline and during follow-up to assess vulvar pain, symptom severity, treatment-related improvement, and central sensitization.

Following completion of baseline assessments, LDN will be dispensed through a mail-order pharmacy. Participants will take 4.5 mg orally once daily for four weeks. Medication instructions and information regarding potential adverse effects will be provided before treatment initiation.

Safety monitoring will occur throughout the treatment period. Participants will be instructed to discontinue study medication and contact the study team promptly in the event of significant or concerning adverse reactions. A study coordinator will conduct an adverse-event and adherence assessment approximately two weeks after treatment initiation. A follow-up clinical assessment will occur approximately four weeks after treatment initiation.

Safety laboratory testing will include a complete blood count and comprehensive metabolic panel at screening and at the end of treatment. Hepatic enzymes, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin, will be assessed at baseline and at the end of treatment and may be repeated when clinically indicated. Treatment-emergent liver enzyme elevations will be followed until resolution or stabilization, as clinically appropriate. Other treatment-emergent adverse events will be monitored until resolution or stabilization.

Participants will be counseled regarding the potential risks associated with naltrexone, including dizziness, somnolence, fatigue, gastrointestinal symptoms, hypersensitivity reactions, mood-related adverse effects, and potential hepatic injury. Counseling will also address the importance of avoiding opioid-containing medications during treatment and the potential risk of opioid withdrawal and opioid overdose following naltrexone exposure. Participants of childbearing potential will receive pregnancy and contraception counseling consistent with the study eligibility requirements and protocol.

The study will include assessment of adherence, treatment-related adverse effects, and changes in pain and symptom measures from baseline to follow-up. Patient-reported treatment improvement will be assessed using the designated global treatment improvement measure. Changes in average NRS and vulvar pain questionnaire scores will also be evaluated.

The study will use descriptive statistics to characterize baseline participant and clinical data. Pre-treatment and post-treatment pain and symptom scores will be compared using appropriate statistical methods. A two-sided alpha level of 0.05 will be used to define statistical significance for inferential analyses. Given the pilot nature and anticipated sample size of approximately 20 participants, analyses will primarily provide estimates of treatment response, variability, and tolerability to inform the design of future studies.

Research procedures will be distinguished from standard clinical care. Routine medical history, physical examination, and clinically indicated pelvic or vulvar evaluation may occur as part of standard clinical care. Study-specific procedures include administration of oral LDN, study-specific questionnaires and assessments, systematic adverse-event monitoring, study-specific follow-up assessments, and collection and analysis of research data.

Study data will be collected and maintained in accordance with applicable institutional policies, regulatory requirements, and privacy protections. Research data will be coded or de-identified as appropriate. Data shared with collaborating investigators at Mayo Clinic may include coded or de-identified demographic, clinical, treatment-response, and adverse-event information. Direct identifiers will not be included in data sets intended for research analysis unless specifically permitted under applicable institutional and regulatory requirements. Data transfers will occur through secure institutional systems, and access will be limited to authorized research personnel. Data retention and destruction will follow institutional requirements, applicable regulations, and the approved study data-management plan.

The study is planned to recruit approximately 20 participants. Recruitment and data collection are anticipated during Quarters 1 through 3 of 2027, followed by data analysis during Quarter 4 of 2027. The anticipated deliverable is a pilot assessment of the safety, tolerability, and potential effectiveness of LDN for vulvodynia. Findings from the pilot study are intended to provide preliminary data regarding treatment response and adverse events and may inform the design and feasibility of a subsequent larger clinical trial.

03

Conditions studied

  • Vulvodynia

Browse trials for

Keywords

  • vulvodynia
  • naltrexone
  • chronic pelvic pain
  • vulvar pain
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 3 months postpartum
  • Diagnosis of moderate to severe vulvodynia as defined by persistent vulvar pain for at least 3 months duration with an unclear etiology (defined by a minimum pain score at baseline using NRS and VPAQ questionnaires).
  • Prior therapy may include conservative management options (vulvar care guidelines, vaginal hormone therapy, neuromodulators etc.)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Positive urine pregnancy test at study entrance, for subjects of
  • Unwillingness to use during treatment and for one week after last dose if subject is of childbearing potential and sexually active with males.
  • Known to naltrexone.
  • Prior or concurrent use of other systemic or topical treatments for vulvodynia (except topical hormonal therapy) within 3 months of enrollment.
  • Pelvic treatment with botulinum toxin injection within the last 12 months prior to the baseline visit
  • Use of opioids in any formulation (including pain medication, cough suppressants, and anti-diarrheal agents) within two weeks prior to study entrance.
  • Positive toxicology screen for opioids at study entrance.
  • Active gynecologic .
  • Elevated hepatic enzymes on screening laboratory assessment ( ≥1.5- fold , AST ≥1.5-fold ULN, alkaline phosphatase ≥1.5-fold ULN, or/or total ≥1.5-fold ULN, with the exception of known Gilbert's disease)
  • Known cirrhosis (compensated or decompensated)
  • Kidney disease defined as estimated (eGFR) \< 60 ml/minute on screening laboratory assessment using the Formula.
  • Any history (past or current) of suicidal ideation or attempt.
  • Evidence of suicidal ideation on baseline screening using the Columbia Suicide Severity Rating Scale (C-SSRS).
  • Uncontrolled depression.
  • Unwillingness to refrain from driving/operating heavy machinery until the effect of the drug on drowsiness/somnolence is determined by the subject.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Low Dose Naltrexone

    4.5 mg oral LDN daily for four weeks

    Drug: Low Dose Naltrexone

Interventions

06

What researchers measure

Primary outcomes

  1. Patient Global Impression of Change

    Primary outcome is the overall improvement in participant's vulvar pain symptoms as assessed by the Patient Global Impression of Change (PGIC) after four weeks of treatment. It is a single question assessment to measure how much a health condition has changed after treatment. Scale 1-7 (1= best outcome, 7 =worst outcome).

    Time frame: 4 weeks

Secondary outcomes

  1. Numerical Rating Scale

    Net change in Numerical Rating Scale (NRS) after four weeks of treatment. NRS allows patients to rate their pain on a scale of 0-10 (0 =no pain, 10= most severe pain).

    Time frame: 4 weeks

  2. Vulvar Pain Assessment Questionnaire

    Net change in Vulvar Pain Assessment Questionnaire (VPAQ) after four weeks of treatment. 38 item questionnaire that uses a 5-point Likert Scale (0-4 with 0= no symptoms 4=worst symptoms)

    Time frame: 4 weeks

  3. CSI

    Net change in Central Sensitization Inventory (CSI) after four weeks of treatment. Consists of 25 health-related questions with possible responses on a 5-point Likert scale (0-4 with 0=never and 4=always). Total score out of 100 with higher number reflecting a worse outcome.

    Time frame: 4 weeks

07

Study locations

2 sites
08

References and documents

Publications

  • Hatfield E, Phillips K, Swidan S, Ashman L. Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. J Am Dent Assoc. 2020 Dec;151(12):891-902.e1. doi: 10.1016/j.adaj.2020.08.019. PubMed 33228882 ↗
  • Rupp A, Young E, Chadwick AL. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023 Nov 2;24(11):1270-1281. doi: 10.1093/pm/pnad074. PubMed 37302106 ↗
  • McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series. J Pain Res. 2023 Jun 14;16:1993-1998. doi: 10.2147/JPR.S389957. eCollection 2023. PubMed 37337611 ↗
  • Levesque A, Riant T, Labat JJ, Ploteau S. Use of High-Concentration Capsaicin Patch for the Treatment of Pelvic Pain: Observational Study of 60 Inpatients. Pain Physician. 2017 Jan-Feb;20(1):E161-E167. PubMed 28072808 ↗
  • Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-158. doi: 10.1016/S0304-3959(01)00349-9. PubMed 11690728 ↗
  • Committee Opinion No 673 Summary: Persistent Vulvar Pain. Obstet Gynecol. 2016 Sep;128(3):676-677. doi: 10.1097/AOG.0000000000001639. PubMed 27548552 ↗
  • Sullender RT, Silverstein RG, Goodwin DM, McClurg AB, Carey ET. Low-dose naltrexone as a treatment for vulvodynia: A case series. Case Rep Womens Health. 2024 Dec 13;45:e00677. doi: 10.1016/j.crwh.2024.e00677. eCollection 2025 Mar. PubMed 39802731 ↗
  • Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. PubMed 24526250 ↗
  • Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low Dose Naltrexone in the Treatment of Fibromyalgia. Curr Rheumatol Rev. 2018;14(2):177-180. doi: 10.2174/1573397113666170321120329. PubMed 28325149 ↗
  • Goldstein AT, Burrows L. Vulvodynia. J Sex Med. 2008 Jan;5(1):5-14; quiz 15. doi: 10.1111/j.1743-6109.2007.00679.x. PubMed 18173761 ↗
  • Harlow BL, Kunitz CG, Nguyen RH, Rydell SA, Turner RM, MacLehose RF. Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions. Am J Obstet Gynecol. 2014 Jan;210(1):40.e1-8. doi: 10.1016/j.ajog.2013.09.033. Epub 2013 Sep 28. PubMed 24080300 ↗
  • Friedrich EG Jr. Vulvar vestibulitis syndrome. J Reprod Med. 1987 Feb;32(2):110-4. PubMed 3560069 ↗
  • Ventolini G. Measuring treatment outcomes in women with vulvodynia. J Clin Med Res. 2011 Apr 4;3(2):59-64. doi: 10.4021/jocmr526w. PubMed 21811531 ↗

Individual participant data

Plan to share: No — Individual participant data will not be made available to outside researchers to protect participant privacy and comply with the institutional consent framework governing this study. Aggregated data supporting the study findings will be published in the manuscript and supplementary files.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore PGICNow Patient Global Impression of ChangeTime frame: 4 weeks
Oct 9, 2026
Secondary outcomes
2 added, 2 removed, 1 description edited
What changed in the outcomes
  • AddedNumerical Rating ScaleTime frame: 4 weeks
  • AddedVulvar Pain Assessment QuestionnaireTime frame: 4 weeks
  • RemovedNRSTime frame: 4 weeks
  • RemovedVPAQTime frame: 4 weeks
  • DescriptionCSI: how it is measured was reworded
Oct 9, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 9, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore PGICNow Patient Global Impression of ChangeTime frame: 4 weeks
    Secondary outcomes 2 added, 2 removed, 1 description edited
    What changed in the outcomes
    • AddedNumerical Rating ScaleTime frame: 4 weeks
    • AddedVulvar Pain Assessment QuestionnaireTime frame: 4 weeks
    • RemovedNRSTime frame: 4 weeks
    • RemovedVPAQTime frame: 4 weeks
    • DescriptionCSI: how it is measured was reworded
    + 1 other change: description
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862400
Collaborators
Mayo Clinic
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion